Immunosenescence and Cancer Vaccines

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2009 Feb 10

PMID 19198836

Citations 6

Authors

Mauro Provinciali

Affiliations

Soon will be listed here.

Abstract

Experimental and clinical data demonstrate that ageing is associated with the gradual deterioration of the immune system, generally referred to as immunosenescence. Age-related immune dysfunction may have an impact not only on the incidence of cancer, but also on the preventive and therapeutic approaches, which are based on immune system activation. Over the last few years the use of immunological measures to prevent cancer in experimental mouse models involving preimmunization with new vaccines against even a poor or apparently non-immunogenic tumour has yielded worse outcomes in older age than in young adults. Different mechanisms, which may be due to age-related numerical or functional dysfunction of immune cells and/or to tumour microenvironmental changes, could be responsible for this defect. This review summarises the impact of immunosenescence on the effectiveness of cancer vaccines, knowledge of cancer immunisation in old age and the potential mechanisms implicated in the poorer effectiveness of anticancer immune-based approaches in advanced age. Several approaches to, and possibilities of correcting the low effectiveness of immunisation procedures in old age are described.

Citing Articles

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.

Provinciali M, Barucca A, Orlando F, Pierpaoli E Sci Rep. 2017; 7(1):3078.

PMID: 28596550 PMC: 5465096. DOI: 10.1038/s41598-017-03286-8.

Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.

Stark F, McCluskie M, Krishnan L Vaccines (Basel). 2016; 4(4).

PMID: 27869670 PMC: 5192364. DOI: 10.3390/vaccines4040044.

Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma.

Sznurkowski J, Zawrocki A, Biernat W Cancer Immunol Immunother. 2013; 63(3):297-303.

PMID: 24368339 PMC: 3928516. DOI: 10.1007/s00262-013-1511-x.

Aging, cancer, and cancer vaccines.

Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E Immun Ageing. 2012; 9(1):4.

PMID: 22510392 PMC: 3353870. DOI: 10.1186/1742-4933-9-4.

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.

Provinciali M, Barucca A, Pierpaoli E, Orlando F, Pierpaoli S, Smorlesi A Cancer Immunol Immunother. 2011; 61(3):363-71.

PMID: 21922332 PMC: 11028531. DOI: 10.1007/s00262-011-1107-2.

References

Walker P, Saas P, Dietrich P . Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997; 158(10):4521-4. View

Sharma S, Dominguez A, Lustgarten J . High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol. 2006; 177(12):8348-55. DOI: 10.4049/jimmunol.177.12.8348. View

Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A . Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine. 2003; 21(9-10):843-8. DOI: 10.1016/s0264-410x(02)00530-3. View

Greenwald R, Freeman G, Sharpe A . The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48. DOI: 10.1146/annurev.immunol.23.021704.115611. View

Groux H, OGarra A, Bigler M, Rouleau M, Antonenko S, De Vries J . A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389(6652):737-42. DOI: 10.1038/39614. View

Provinciali M, Fabris N, Pieri C . Improvement of natural killer cell activity by in vitro active lipids (AL 721) administration in old mice. Mech Ageing Dev. 1990; 52(2-3):245-54. DOI: 10.1016/0047-6374(90)90128-3. View

Pertovaara M, Raitala A, Lehtimaki T, Karhunen P, Oja S, Jylha M . Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev. 2006; 127(5):497-9. DOI: 10.1016/j.mad.2006.01.020. View

Pawelec G, Solana R . Immunosenescence. Immunol Today. 1997; 18(11):514-6. DOI: 10.1016/s0167-5699(97)01145-6. View

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E . Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 2004; 64(8):2858-64. DOI: 10.1158/0008-5472.can-03-2962. View

10.

Sharma S, Dominguez A, Lustgarten J . Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol. 2005; 41(1):78-84. DOI: 10.1016/j.exger.2005.10.002. View

11.

Carter L, Fouser L, Jussif J, Fitz L, Deng B, Wood C . PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002; 32(3):634-43. DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9. View

12.

Bunt S, Yang L, Sinha P, Clements V, Leips J, Ostrand-Rosenberg S . Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007; 67(20):10019-26. PMC: 4402704. DOI: 10.1158/0008-5472.CAN-07-2354. View

13.

Gregg R, Smith C, CLARK F, Dunnion D, Khan N, Chakraverty R . The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol. 2005; 140(3):540-6. PMC: 1809384. DOI: 10.1111/j.1365-2249.2005.02798.x. View

14.

Donnini A, Argentati K, Mancini R, Smorlesi A, Bartozzi B, Bernardini G . Phenotype, antigen-presenting capacity, and migration of antigen-presenting cells in young and old age. Exp Gerontol. 2002; 37(8-9):1097-112. DOI: 10.1016/s0531-5565(02)00087-6. View

15.

Oshikawa K, Shi F, Rakhmilevich A, Sondel P, Mahvi D, Yang N . Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci U S A. 1999; 96(23):13351-6. PMC: 23951. DOI: 10.1073/pnas.96.23.13351. View

16.

Kabelitz D, Wesch D, He W . Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007; 67(1):5-8. DOI: 10.1158/0008-5472.CAN-06-3069. View

17.

Jones E, Dahm-Vicker M, Simon A, Green A, Powrie F, Cerundolo V . Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2003; 2:1. View

18.

Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P . CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A. 2002; 99(13):8832-7. PMC: 124384. DOI: 10.1073/pnas.132254399. View

19.

Zamanakou M, Germenis A, Karanikas V . Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett. 2007; 111(2):69-75. DOI: 10.1016/j.imlet.2007.06.001. View

20.

Whiteside T . The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12. PMC: 3689267. DOI: 10.1038/onc.2008.271. View